Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP744937.RA_FZD2pkr_Wl6kOig3jhFUTIyYHDdhAKXXrjPTIDwMqA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP744937.RA_FZD2pkr_Wl6kOig3jhFUTIyYHDdhAKXXrjPTIDwMqA130_assertion type Assertion NP744937.RA_FZD2pkr_Wl6kOig3jhFUTIyYHDdhAKXXrjPTIDwMqA130_head.
- NP744937.RA_FZD2pkr_Wl6kOig3jhFUTIyYHDdhAKXXrjPTIDwMqA130_assertion description "[Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP744937.RA_FZD2pkr_Wl6kOig3jhFUTIyYHDdhAKXXrjPTIDwMqA130_provenance.
- NP744937.RA_FZD2pkr_Wl6kOig3jhFUTIyYHDdhAKXXrjPTIDwMqA130_assertion evidence source_evidence_literature NP744937.RA_FZD2pkr_Wl6kOig3jhFUTIyYHDdhAKXXrjPTIDwMqA130_provenance.
- NP744937.RA_FZD2pkr_Wl6kOig3jhFUTIyYHDdhAKXXrjPTIDwMqA130_assertion SIO_000772 22021366 NP744937.RA_FZD2pkr_Wl6kOig3jhFUTIyYHDdhAKXXrjPTIDwMqA130_provenance.
- NP744937.RA_FZD2pkr_Wl6kOig3jhFUTIyYHDdhAKXXrjPTIDwMqA130_assertion wasDerivedFrom befree-20140225 NP744937.RA_FZD2pkr_Wl6kOig3jhFUTIyYHDdhAKXXrjPTIDwMqA130_provenance.
- NP744937.RA_FZD2pkr_Wl6kOig3jhFUTIyYHDdhAKXXrjPTIDwMqA130_assertion wasGeneratedBy ECO_0000203 NP744937.RA_FZD2pkr_Wl6kOig3jhFUTIyYHDdhAKXXrjPTIDwMqA130_provenance.